This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

FujiFilm Diosynth plans to produce Regeneron's biologic medicines over 10 years in its Holly Springs facility, which is ...

On Tuesday, Fujifilm Diosynth announced a 10-year agreement worth more than $3 billion to make medicines for the New York drugmaker Regeneron in the Triangle. Regeneron is the facility’s third ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

Fujifilm Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced a 10-year manufacturing supply ...